Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 921 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCD Clear all

Conditions: Sickle Cell Disease, Cerebral Stroke
Interventions: Carbon Dioxide; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 15 Years to 44 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Memphis, Tennessee

Conditions: Sickle Cell Disease & Thalassemia
Interventions: NiCord; Drug
Lead sponsor: Gamida Cell ltd; Industry
Eligibility: 2 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: New York, New York • Durham, North Carolina • Houston, Texas

Conditions: Sickle Cell Trait
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sickle Cell Disease
Interventions: MRI, Transthoracic Echocardiography, tonometry, EKG; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sickle Cell Trait
Interventions: SCT Documentation and Disclosure Toolkit (SCT-DD); Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: Not listed
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Sickle Cell Disease
Interventions: Prasugrel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 20
States / cities: Oakland, California • Palo Alto, California • Hartford, Connecticut + 16 more

Conditions: Cardiovascular Diseases, Myocardial Infarction, Heart Diseases, Death, Sudden, Cardiac
Interventions: Cardiopulmonary Resuscitation, Automatic External Defibrillation; Other · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 7,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sickle Cell Disease
Interventions: Albuterol; Drug
Lead sponsor: Duke University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sickle Cell Disease, Stress, Pain
Interventions: Guided Relaxation video clip, Sickle Cell Disease Experience Discussion; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)
Interventions: PK-optimized oral hydroxyurea at MTD until 15 years of age.; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Months and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Sickle Cell Anemia
Interventions: beet juice (Unbeetable); Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 19 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sickle Cell Disease, Obesity, Childhood, Hypertension, Hyperlipidemia in Children, Hyperglycemia
Interventions: Not listed
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 10 Years to 19 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Sickle Cell Disease
Interventions: ICL670; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 31
States / cities: Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more

Conditions: Sickle Cell Disease
Interventions: GBT440; Drug
Lead sponsor: Global Blood Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Sickle Cell Disease
Interventions: INCB059872; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Miami, Florida • Tamarac, Florida • Chicago, Illinois + 3 more

Conditions: Epilepsy, Sudden Cardiac Death
Interventions: A change or titration in the current or frequency settings of the VNS therapy system.; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ventricular Tachycardia, Cardiovascular Diseases, Arrythmia, CVD
Interventions: Not listed
Lead sponsor: CardioDx; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sickle Cell Anemia
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Sickle Cell Disease
Interventions: Defibrotide; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 6 Months to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Valhalla, New York + 1 more

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Anemia
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 8 Years to 20 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina

Conditions: Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: levocarnitine, placebo; Dietary Supplement · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 116
States / cities: Palo Alto, California • Stanford, California • Danbury, Connecticut + 85 more

Search by objective public record fields.

Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography

Re-Aiming at Hydroxyurea Adherence for Sickle Cell With mHealth

Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

Sickle Cell Trait in Football Players

The Link Between Anemia and Deficits in Memory and Attention in Individuals With Sickle Cell Disease

Cardiovascular Complications of Sickle Cell Disease

Increasing Documentation and Disclosure of Sickle Cell Trait Status: An Implementation Science Approach

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Home Use of Automatic External Defibrillators to Treat Sudden Cardiac Arrest

Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease

The Feasibility of the PAINReportIt Guided Relaxation Intervention-Outpatient

Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

Study of Beet Juice for Patients With Sickle Cell Anemia

Obesity in Pediatric Sickle Cell Disease: A New Phenomenon

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

Optimization of VNS in Epileptic Patients to Induce Cardioprotection

Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial

The Role of Endothelin-1 in Sickle Cell Disease

Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

Motivations, Expectations, and Decision-making of Sickle Cell Patients in Clinical Research

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Levocarnitine in Treating Fatigue in Cancer Patients